Persistence of SARS-CoV-2 has been proposed as a biological driver of Long COVID, a disabling chronic illness with no proven treatments. We conducted an exploratory, placebo-controlled, double-blind, 2:1 randomized mechanistic trial (NCT05877508) of the SARS-CoV-2-specific monoclonal antibody AER002 in 36 participa...
M. Peluso, Dylan Ryder, T. Dalhuisen et al.· Nature Communications· 0 citations
Hundreds of recall and de novo neutralizing monoclonal antibodies are isolated and characterized after sequential exposures to SARS-CoV-2 variants in ancestral-imprinted humans to reveal the distinct contributions of recall and de novo antibodies to a balanced immune response and underscore the benefit of updated boost...
T. Johnston, Shuk-Hang Li, M. Painter et al.· Nature Immunology· 2 citations
The dependence of effective variant-specific antibodies on vaccination history is shown which may explain birth-year influence on differential susceptibility to SARS-CoV-2 variants XFG and BA.3.3.2, and it is suggested that vaccination regimens in children should prioritize neutralization breadth.
T. Johnston, Rahul Subramanian, Wakinyan Benhamou et al.· bioRxiv· 0 citations
This work introduces CytoGate-Bench, a benchmark that reformulates this per-step procedure as a zero-shot, panel-agnostic task for large language models, and contributes a public benchmark that tests precisely that ability across 11 human cohorts.
Jaesik Kim, Byounghan Lee, N. Ahn et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
